Generate Biomedicines, Inc.
15.52USD
-0.3800 (-2.39%)
Revenue
| (USD) | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| FY | — | — | 29.7M | 23.8M |
| Q1 | — | 8.8M | 7.2M | — |
| Q2 | — | 10.1M | 6.3M | — |
| Q3 | — | — | 7.8M | — |
| Q4 | — | — | 7.7M | — |
Revenue
| (USD) | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| FY | — | — | -2.30 | -2.28 |
| Q1 | — | -1.62 | -1.07 | — |
| Q2 | — | -1.94 | -.520 | — |
| Q3 | — | — | -.545 | — |
| Q4 | — | — | -.568 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.